TwoStep
Oncology Therapeutics
Overview
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Funding and backers
Team
11-50
employees, estimated range
Backers
2
NFX, M Ventures
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 2024
Website went live first capture in the Wayback Machine
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
ETX-19477 is a selective PARG inhibitor designed to address DNA damage response vulnerabilities and expand precision treatment options for…
BetaGlue Therapeutics — YntraDose®: a one-time, image-guided Yttrium-90 injection designed for durable local tumor control alongside…
We are solving a major bottleneck in the field of targeted biotherapeutics in oncology – the identification of novel targets for the…
CasInvent Pharma | CasInvent Pharma. Fighting resistant tumors with best-in-class inhibitors of casein kinase 1 (CK1).
Enara Bio is a science-led immunotherapy company developing novel T-cell directed cancer therapies. Its EDAPT platform discovers Dark…
Targeting the Tumor Ecosystem to address cancer drug resistance and improve patients’ lives.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
M VenturesVia a fund
NFXVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Biotech Fundraising Breaking the Barrier of ADC 'Tumor Penetration and Toxicity'? Stanford-born TwoStep Therapeutics Raises $62.5 Million in Series A & PDC 'TS-104' Receives FDA IND ClearanceJINバイオDD職人
Since the global blockbuster success of Daiichi Sankyo's Enhertu, the world of biotech investment has been buzzing with an unprecedented 'ADC boom.' However, behind that frenzy, clinicians and medicinal chemists have likely been hitting the same wall all
Read more
Report
诺奖得主押注PDC：TwoStep完成6250万美元A轮TS-104获批IND
9月9日加州圣卡洛斯的生物技术公司TwoStep Therapeutics同时扔出两个消息：6250万美元超额认购A轮融资到账FDA批准了其领先肽偶联药物PDCTS-104的IND申请TwoStep…
Read more
Report
TwoStep Therapeutics Raises $62.5 Million Series A As FDA Clears TS-104 For Phase 1 Cancer Trial
TwoStep Therapeutics has raised an oversubscribed $62.5 million Series A and received FDA clearance for the Investigational New Drug application for TS-104, its lead multi-specific peptide-drug conjugate for solid tumors.
Read more
Report
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
TwoStep will begin a Phase I study of TS-104, with patient enrolment expected to commence later this year.
Read more
Report
TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate
SAN CARLOS, Calif., September 09, 2026--TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate
Read more
Report
TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate
Read more
Report
TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate
Read more
Report
TwoStep Therapeutics: $6.5 Million Secured To Advance Applicable Targeting Platform for Solid Tumors
TwoStep Therapeutics, a biotechnology company developing new targeted therapeutics for solid tumors, announced its official launch following a successful $6.5 million seed round led by NFX, with participation from other investors including 2048 Ventures,
Read more
Report
Show more news